- Home
- IMNN
IMNN
Imunon Inc.
as 12-18-2024 3:36pm EST
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAWRENCEVILLE |
| Market Cap: | 12.2M | IPO Year: | 1985 |
| Target Price: | $20.50 | AVG Volume (30 days): | 191.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $3.65 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Imunon Inc. News
IMNN Breaking Stock News: Dive into IMNN Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Zacks Small Cap Research
23 days ago
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…
GlobeNewswire
23 days ago
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
Zacks Small Cap Research
a month ago
IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial
GuruFocus.com
a month ago
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...
GlobeNewswire
a month ago
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
GlobeNewswire
a month ago
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
2 months ago
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
Compare IMNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNN Imunon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.